Blog - Page 876 of 5707 - QualityStocks

ThursdayOct 06, 2022 1:59 pm

QualityStocksNewsBreaks – Sugarmade Inc. (SGMD) Lays Foundation for Significantly Expanded Manufacturing, Distribution Infrastructure

Sugarmade (OTC: SGMD), an emerging leader in the licensed cannabis sector, recently signed a management services agreement (“MSA”), marking a key milestone as the company actively strengthens its position in the California cannabis space. “SGMD signed the MSA through its subsidiary, SugarRush, which entered into the agreement with Canndis Inc., a California cannabis micro license holder. Canndis holds a license that covers delivery, manufacturing, distribution, and cultivation rights, and the agreement will enable Sugarmade to expand its manufacturing and distribution footprint,” a recent article reads. “Sugarmade is anticipating harvesting [its first crop], an accomplishment made possible through the company’s acquisition…

ThursdayOct 06, 2022 1:09 pm

QualityStocksNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate at Upcoming Dawson James Small Cap Growth Conference

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is scheduled to participate in the 7th annual Dawson James Small Cap Growth Conference. Silo Pharma CEO Eric Weisblum will present at the event, which is scheduled for Oct. 12, 2022, in Jupiter, Florida. Weisblum’s presentation will include an overview of Silo Pharma’s acquisition and development of intellectual property and technology rights from leading universities and researchers, including the use of the psychedelic drugs. The presentation will also feature a summary of Silo’s the diversified pipeline, which is focused on underserved rare disease,…

ThursdayOct 06, 2022 12:59 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today provided a recap of its concussion drug development program. Concussions affect millions worldwide and represent an ‘unmet’ medical need, while repetitive concussions can increase the risk of developing chronic traumatic encephalopathy (“CTE”) and other neuropsychiatric disorders. Since acquisition of the intellectual property and all rights to the drug on March 1, 2021, Odyssey has made significant progress in its development program. Among many key milestones provided in the update, the company announced successful completion of the pre-clinical toxicology program and IND enabling safety studies for a…

ThursdayOct 06, 2022 12:40 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Platform to Add 24/7 Heart Monitoring Capability

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced the expansion of its product portfolio pipeline to serve the growing cardiac device wearable technology market by bringing clinically relevant diagnostic information to patients and clinicians. According to the update, the product pipeline advancement allows for the addition of arrhythmia detection capabilities to address the multibillion global market for atrial fibrillation and other arrhythmia monitoring. “Adding smartwatch connectivity to our platform is a significant development as it extends our portfolio by enabling 24/7 heart monitoring…

ThursdayOct 06, 2022 12:21 pm

QualityStocksNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Announces New CFO Appointment

EverGen (TSX.V: EVGN) (OTCQB: EVGIF) today announced its appointment announce the appointment of Sean Hennessy as chief financial officer, effective immediately. Sean previously held the position of vice president, finance and controller. “We are excited to add Sean to our executive team,” said Chase Edgelow, CEO of EverGen. “Sean brings extensive financial and strategic experience to EverGen. He has been deeply involved with EverGen since the beginning of this year and this move is a seamless transition to bring our CFO role in-house. We would like to thank Natasha Monk, our interim CFO and partner at Affirm LLP, who will…

ThursdayOct 06, 2022 12:01 pm

QualityStocksNewsBreaks – BlockQuarry Corp. (BLQC) Q2, Q3 Reports Covered in Syndicated Broadcast

BlockQuarry (OTC: BLQC), a Texas-based company with commercial-stage operations in cryptocurrency mine hosting and self-mining in the southeast United States, is featured in an audio news broadcast released by NetworkNewsAudio (“NNA”). The latest release discusses BLQC’s report on its provisional and unaudited Q3 performance projections and includes highlights from its financial performance for the second quarter, or the three-month period ended June 30, 2022. The broadcast discusses the company’s revenue, which exceeded $1.5 million for Q2, up almost 8,000% year over year, as well as its total assets, which increased to nearly $11 million, up nearly 6,000%. The company also announced…

ThursdayOct 06, 2022 11:15 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cybin continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel drug candidates. The company has more than 20 active patent filings — 14 of which were filed this year alone — across six patent families. Additionally, Cybin has entered into multiple licensing agreements that provide additional access to IP from over 15…

ThursdayOct 06, 2022 10:30 am

Weathering the Storm: GeoSolar Technologies Inc. Electrifying Highly Efficient Homes

Hurricane Ian is the latest reminder that 83% of all major power outages are weather related GeoSolar Technologies SmartGreen(TM) homes include rooftop solar panels, battery systems, geothermal loops and electric air pump, premium insulation and more Installing a SmartGreen(TM) system reduces emissions by 8 tons annually and can eliminate energy-related utility bills Devastating weather events like Hurricane Ian regularly leave millions of people throughout the path of the storm without power. In fact, it weather is nearly always responsible for major power outages, the culprit in 83% between 2000 and 2021, according to Climate Central. This begs the question of…

ThursdayOct 06, 2022 9:45 am

REZYFi, Inc. Addressing the Financial Needs of the ‘Largest Underbanked Industry’ in the US

REZYFi, Inc. is a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businesses The company operates through its two subsidiaries, REZYFi Lending, which is now focused on cannabis commercial real estate lending, and ResMac, Inc., a traditional mortgage origination, correspondent, and servicing business REZYFi seeks to provide access to financial services to the cannabis industry, which is still largely underserved because large financial companies have continuously shied away due to the illegality of cannabis at the federal level The US cannabis industry is expected to generate $52.6 billion in sales by 2026, up from…

ThursdayOct 06, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing…

Site Search

Company Search